for the main comparison.

LDL cholesterol lowering efficacy of fluvastatin
Patient or population: participants with normal or abnormal lipid profiles Settings: ambulatory care Intervention: fluvastatin Comparison: LDL cholesterol percentage change from baseline for all trials
Outcomes	Anticipated absolute effects mmol/L (95%CI)		Percent reduction (95% CI) %	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Before exposure to fluvastatin1	After exposure to fluvastatin
LDL‐cholesterol fluvastatin 10 mg/day	4.81 (4.44 to 5.17)	4.08 (3.98 to 4.16)	15.2 (17.1 to 13.4)	595 (6)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 14.8%. Randomised and before and after design not different P = 0.94.
LDL‐cholesterol fluvastatin 20 mg/day	4.87 (4.54 to 5.21)	3.90 (3.88 to 3.91)	20.0 (19.7 to 20.3)	9010 (55)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 20.8%. Randomised and before and after design not different P = 0.16.
LDL‐cholesterol fluvastatin 40 mg/day	4.74 (4.41 to 5.06)	3.51 (3.48 to 3.54)	25.9 (25.3 to 26.5)	3658 (57)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 26.8%. Randomised and before and after design not different P = 0.58.
LDL‐cholesterol fluvastatin 80 mg/day	4.80 (4.47 to 5.13)	3.13 (3.10 to 3.15)	34.9 (35.5 to 34.3)	4928 (32)	⊕⊕⊕⊕ high	Effect predicted from log dose‐response equation is 32.8%. Randomised and before and after design not different P = 0.07.
CI: Confidence interval
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

1. Mean baseline values.